Access to Thalidomide for the Treatment of Multiple Myeloma in Canada: Physician Behaviours and Ethical Implications
Current oncology (Toronto, Ont.) 2010 Aug; 17(4): 11-9
Multiple myeloma is an incurable malignancy. Since the late 1990s, its management has changed with the introduction of novel agents. Thalidomide, which is often called a "novel" therapy, has significantly prolonged survival in multiple myeloma and is considered worldwide to be part of standard of care in this disease. However, thalidomide is not approved in Canada, leading to problems with drug access for patients.
Showing items related by title, author, creator and subject.